Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages 1367-1375

  Wu, Grace Hui Min ^a   Auvinen, Anssi ^a   Määttänen, Liisa ^b   Tammela, Teuvo L J ^c   Stenman, Ulf Hãkan ^d,e   Hakama, Matti ^a,b   Yen, Amy Ming Fang ^f,g   Chen, Hsiu Hsi ^a,g  

^a UNIVERSITY OF TAMPERE   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

mass screening; prostate specific antigen; prostatic neoplasms; randomized controlled trial; sensitivity and specificity; stochastic processes

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIGITAL RECTAL EXAMINATION; EPIDEMIOLOGICAL DATA; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY;

AGED; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK;

EID: 84864126860     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27340     Document Type: Article

References (29)

1. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH,. Quality of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-35.
2. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H,. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20: 680-8.
3. Franks LM,. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603-16.
4. Carter HB, Piantadosi S, Isaacs JT,. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990; 143: 742-6.
5. Watanabe M, Nakayame T, Shiraishi T, Stemmermann GN, Yatani R,. Comparative study of prostate cancer in Japan versus the United States: a review. Urol Oncol 2000; 5: 274-83.
6. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK, eds. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008.
7. Zappa M, Ciatto S, Bonardi R, Mazzotta A,. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998; 9: 1297-300.
8. McGregor M, Hanley JA, Boivin JF, McLean RG,. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998; 159: 1368-72.
9. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ,. Overdetection due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-90.
10. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ,. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78.
11. Davidov O, Zelen M,. Overdetection in early detection programs. Biostatistics 2004; 5: 603-13.
12. Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi C, Crocetti E, Zappa M,. Determining overdetection by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 2005; 41: 411-15.
13. Pashayan N, Powles J, Brown C, Duffy SW,. Excess cases of prostate cancer and estimated overdetection associated with PSA testing in East Anglia. Br J Cancer 2006; 95: 401-5.
14. Tsodikov A, Szabo A, Wegelin J,. A population model of prostate cancer incidence. Stat Med 2006; 25: 2846-66.
15. Telesca D, Etzioni R, Gulati R,. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2006; 64: 10-19.
16. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H,. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 374-83.
17. Finne P, Stenman UH, Määttänen L,. The Finnish trial of prostate cancer screening: where are we now? BJU Int 2003; 92 (Suppl.): 22-6.
18. Andriole GL, Crawford ED, Grubb RL, III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-19.
19. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
20. Chen THH, Duffy SW, Tabar L,. A Markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. Statistician 1996; 45: 307-17.
21. McAlister FA, Straus SE, Guyatt GH, Haynes RB,. Users' guides to the medical literature. XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA 2000; 283: 2829-36.
22. Efron B, Tibshirani RJ,. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
23. Törnblom M, Eriksson H, Franzén S, Gustafsson O, Lilja H, Norming U, Hugosson J,. Lead time associated with screening for prostate cancer. Int J Cancer 2004; 108: 122-9.
24. Perrin P, Maquet JH, Bringeon G, Devonec M,. Screening for prostate cancer. Comparison of transrectal ultrasound, prostate specific antigen and rectal examination. Br J Urol 1991; 68: 263-5.
25. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D,. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assessm 1997; 1: 1-96.
26. Emiliozzi P, Scarpone P, DePaula F,. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 vs. 12 core transperineal prostate biopsy. J Urol 2004; 71: 197-9.
27. Hakama M, Auvinen A, Day NE, Miller AB,. Sensitivity in cancer screening. J Med Screen 2007; 14: 174-7.
28. Auvinen A, Määttänen L, Finne P, Stenman UH, Aro J, Juusela H, Rannikko S, Tammela TL, Hakama M,. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. Int J Cancer 2004; 111: 940-3.
29. Gann PH, Hennekens CH, Stampfer MJ,. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995; 273: 289-94.